DATE IBC Meeting Minutes

Prepared by HM, LM and LD

Meeting Minutes

Date: Wednesday, April 20, 2022
Time: 10:00 AM – 12:00 PM
Location: Zoom

Members Present:
1. Jim Boonyaratanakornkit, Allergy and Infectious Diseases
2. Thea Brabb, Comparative Medicine (Animal Containment Expert)
3. Jason Cantera (Community Member)
4. Lesley Colby, Comparative Medicine (Animal Containment Expert)
5. Lesley Decker, Environmental Health & Safety (Biosafety Officer)
6. Richard Grant, Washington National Primate Research Center
7. Kevin Hybiske, Allergy and Infectious Diseases (IBC Vice Chair)
8. Scott Meschke, Environmental & Occupational Health Sciences
9. Susan Parazzoli (Community Member)
10. Stephen Libby (Animal containment expert)
11. Paul Swenson, Seattle-King Co. Dept. of Public Health (Community Member)

Commonly Used Abbreviations
IBC: Institutional Biosafety Committee
BSO: Biological Safety Officer
BUA: Biological Use Authorization
BSL: biosafety level
PI: Principal Investigator
IACUC: Institutional Animal Care and Use Committee
NIH: National Institutes of Health
DURC: Dual Use Research of Concern
SOP: standard operating procedure
1. **CALL TO ORDER:** The Institutional Biosafety Committee (IBC) Vice Chair called the meeting to order at 10:02 a.m. A quorum was present.

2. **REMINDER:** The IBC Vice Chair reminded attendees that any notes that they retain are subject to public disclosure. A statement was also made about conflict of interest and voting on research proposals as described in the IBC Charter. This includes sharing a grant or a familial relationship.

3. **APPROVAL OF MINUTES:**
   - The IBC Vice Chair sought a motion to approve the minutes from the March 16, 2022, meeting.
   - A member made a motion to approve the March 16, 2022, minutes. Another member seconded the motion.
   - The committee voted to approve the March 16, 2022, meeting minutes with one abstention and two members not submitting votes.

4. **OLD BUSINESS:**
   - At the February 16, 2022 meeting, the committee voted to approve Dr. Zhang’s BUA pending successful completion of inspection. The biosafety officer has sent out this BUA.
   - At the March 16, 2022 meeting, the committee voted to approve Dr. Bajjalieh’s BUA pending completion of lab inspection and required training. The biosafety officer has not sent out this BUA yet.
   - At the March 16, 2022 meeting, the committee voted to approve Dr. Giachelli’s BUA pending completion of IACUC. The biosafety officer has not sent out this BUA yet.
   - At the March 16, 2022 meeting, the committee voted to approve Dr. Gottlieb’s BUA pending clarification on conferring resistance to treatments in HIV strains. The biosafety officer has sent out this BUA.
   - At the March 16, 2022 meeting, the committee voted to approve Dr. Greenberg’s BUA pending clarification regarding bacterial strain antibiotic resistance. The biosafety officer has sent out this BUA.
   - At the March 16, 2022 meeting, the committee voted to approve Dr. Harwood’s BUA pending completion of lab inspection and clarification regarding bacterial strain antibiotic resistance. The biosafety officer has sent out this BUA.
   - At the March 16, 2022 meeting, the committee voted to approve Dr. Hladik’s BUA pending completion of correction to the BUA letter. This BUA has been sent out.
   - At the March 16, 2022 meeting, the committee voted to approve Dr. Horwitz’s BUA pending completion of BUA application edits for in vivo use of Sindbis viral vectors. The biosafety officer has sent out this BUA.
   - At the March 16, 2022 meeting, the committee voted to approve Dr. Kavanagh’s BUA pending completion of lab inspection. The biosafety officer has sent out this BUA.
   - At the March 16, 2022 meeting, the committee voted to approve Dr. Kwon’s BUA pending completion of lab inspection. The biosafety officer has sent out this BUA.
   - At the March 16, 2022 meeting, the committee voted to approve Dr. Merz’s BUA pending completion of lab inspection. The biosafety officer has sent out this BUA.
   - At the March 16, 2022 meeting, the committee voted to approve Dr. Morrissey’s BUA pending completion of lab inspection and an edit to the BUA letter. The biosafety officer has sent out this BUA.
   - At the March 16, 2022 meeting, the committee voted to approve Dr. Van Voorhis’ BUA pending completion of pending resolution of the remaining lab inspection items and pending completion of IACUC. The biosafety officer has not sent out this BUA yet.
• At the March 16, 2022 meeting, the committee voted to approve Dr. Skerrett’s BUA pending clarification on if strain has antibiotic resistance marker. The biosafety officer has sent out this BUA.

5. BIOSAFETY OFFICER (BSO) REPORT: The Biosafety Officer Report includes (1) projects involving recombinant or synthetic nucleic acids covered under section III-E and III-F of the NIH Guidelines, (2) proposals involving non-recombinant biohazardous agents requiring BSL-1 and BSL-2 containment, and (3) administrative updates, such as room additions.

a. Biosafety Officer Report

• Dr. Ho added in vitro work at the Pathology Flow Cytometry Core facility to the BUA Mechanisms of targeting Drugs to the Lymphatics.
• Dr. Murphy added procedures and SOPs for Anopheles mosquitoes feeding on non-human primates infected with Plasmodium knowlesi in primate center to the BUA NHP study.
• Dr. Rajakovich received approval for a new BUA Discovery and characterization of enzymes and metabolism in microbiomes for work with non-parthenogenic K-12 E. coli strains, non-pathogenic E. coli strains, and Risk Group 1 recombinant and non-recombinant bacteria.
• Dr. Fu renewed the BUA Multimodal optical microscopy for work with human blood tissue, body fluids, cell lines in vitro and in vivo in mouse models.
• Dr. Berndt added Ellison Stem Cell Core facility rooms to the BUA Screening and engineering of fluorescent biosensors for approved human induced pluripotent stem cells.
• Dr. Hanson received approval for a new BUA Alzheimer’s Lipid Metabolism lab for in vitro work with human blood, tissue, body fluid, and cell lines.
• Dr. Koelle added wildtype human Rhinovirus A, B, and C to the BUA Koelle Laboratory at UW for in vitro work.
• Dr. Davis renewed the BUA Molecular Analysis of Chromosome Segregation for in vitro work with recombinant baculovirus, K-12 E. coli strains, E. coli strains, and saccharomyces.
• Dr. Patton renewed the BUA Sexually Transmitted Disease Prevention- Primate Unit for work with Chlamydia trachomatis in macaques.
• Dr. Fuller added Hepatitis B to the BUA DNA Vaccine Therapy for in vitro use to approved rooms.
• Dr. Bammler renewed the BUA Generating data for large scale molecular epidemiology studies using genotyping capabilities and gene expression profiling for work with human and non-human primate blood, tissue, body fluids, and cell lines.
• Dr. Bruce renewed the BUA Mapping Protein-Protein Interaction Network in Human Serum, sputum, Cancer Cells, and Bacterial Cells for work with Risk Group 2 bacteria.
• Dr. Juul renewed the BUA Neonatal Neuroprotection for work with human and non-human primate blood, tissue, body fluids, and cell lines.
• Dr. Posner renewed the BUA Point of Care HIV Viral Load Test for work with Chlamydia trachomatis, HIV, SARS-CoV-2 nucleic acid and inactivated tissue, and human blood, tissue, body fluids, and cell lines.
• Dr. Hyde added in vitro work with recombinant SARS-CoV-2 and work with recombinant Ross River virus approved in the January IBC meeting to the BUA Contribution of virus-host interactions to viral pathogenesis (BSL3, non-select).
• Dr. Murry registered CRISPR/Cas9 modified human induced pluripotent stem cells to the BUA Myocardial Infarct Repair in Rats.
• Dr. Gale added fixed tissue samples of Mycobacterium tuberculosis, Human Immunodeficiency Virus, Influenza, Zika virus, and West Nile virus for in vitro use to the BUA The Host Response to Virus Infection.
• Dr. Skerrett is moving approved Risk Group 1 and 2 agents to facilities in HR&T for the BUA Host Defense Against Bacterial Pneumonia.
• Dr. Sims received approval as the new PI of a previously approved BUA Propagation of mammalian cells in tissue culture and preparation of frozen stocks for in vitro work with human and non-human primate blood, tissue, body fluids, and cell lines.
• Dr. Sims received approval as the new PI of a previously approved BUA Testing SARS-CoV-2 Inactivation by RNA Extraction Buffers for in vitro work with SARS-CoV-2 and non-human primate blood, tissue, body fluids, and cell lines.
• Dr. Sims received approval as the new PI of a previously approved BUA Evaluation of multi-omics data in SARS-CoV-2 infected cells for in vitro work with human and non-human primate blood, tissue, body fluids, and cell lines and BSL-3 recombinant SARS-CoV-2.
• Dr. Sims received approval as the new PI of a previously approved BUA Evaluation of CoV lipidomics data and how MERS-CoV regulates the innate immune response in primary human lung cells for in vitro work with human and non-human primate blood, tissue, body fluid and cell lines and BSL-3 recombinant MERS-CoV and SARS-CoV.
• Dr. Fujise registered new gene inserts for third generation lentiviral vectors to the BUA Study of Fortilin.
• Dr. Tian added the Immunology Cell Analysis Facility for use of previously approved agents for the BUA Energetics and Metabolism of the Heart.
• Dr. Hyde added in vitro work with recombinant Venezuelan equine encephalitis virus. This approval only includes genetic mutations that are not expected to increase virulence. This approval does not include TC83 5'UTR mutants (TC83(A3G)) and TC83(A3G)3'UTR chimeras. These changes were approved in the January IBC meeting for the BUA Contribution of virus-host interactions to viral pathogenesis (BSL3, non-select).
• Dr. Waldorf was approved for a new BUA Experimental Model of Viral Induced Brain Injury for use of Zika Virus in macaques, Sendai virus in vitro, and human and non-human primate blood, tissue, body fluids, and cell lines.
• Dr. Salipante added non-recombinant Treponema pallidum.
• Dr. Fujise added the use of SLU 3.1 Cell Analysis Facility with previously approved agents to the BUA Study of Fortilin.
• Dr. Vojtech added the use of SLU 3.1 Cell Analysis Facility with previously approved agents to the BUA Mechanisms of sexual virus transmission.
• Dr. Law renewed the BUA Human neural stem cells and hypothermia in a rat model of HIE for use of human blood, tissue, body fluids and cell lines.
• Dr. Murry added the use of the Foege Flow Lab to the BUA Myocardial Infarct Repair in Rats.
• Dr. Meschke added a large number of Risk Group 1 and 2 organisms to the BUA Detection and Characterization of Pathogens in Environmental Media.
• Dr. Fujise added a new room for in vivo use of adeno-associated viral vectors with oncogene inserts in mice to the BUA Study of Fortilin.
• The IBC Vice Chair a motion to approve this month’s Biosafety Officer Report.
• A member made a motion to approve this month’s Biosafety Officer Report. Another member seconded the motion.
• The Committee voted unanimously to approve this month’s Biosafety Officer Report.

6. BSL-3 INACTIVATION REPORT
- Dr. Hawn requested Trizol inactivation of Mycobacterium tuberculosis.
- The subcommittee reviewed procedure and inactivation data provided by the lab and approved the request.
- The IBC Vice Chair made a motion to approve this month’s BSL-3 Inactivation Report.
- A member made a motion to approve this month’s BSL-3 Inactivation Report. Another member seconded the motion.
- The committee voted to approve this month’s BSL-3 Inactivation Report with one member not submitting a vote.

7. INDIVIDUAL PROJECT REVIEWS

a. Carr, Rotonya, new, *The Pathogenesis of Insulin Resistance in Alcoholic Liver Disease*
- The assigned IBC primary reviewer presented the primary review.
- This lab studies how the accumulation of lipids within the liver in both alcoholic and non-alcoholic liver disease can lead to insulin resistance.
- This lab works with AAV viral vectors and human blood, tissue, and cell lines.
- A lab inspection has been completed but a response from the lab to resolve the deficiencies is still pending.
- All required trainings are complete.
- The committee examined the draft BUA letter.
- The IBC primary reviewer made a motion to approve the draft BUA for Dr. Carr.
- The committee voted unanimously to approve the draft BUA for Dr. Carr pending completion of a successful lab inspection.

b. Daggett, Valerie, renewal, *Peptide-based diagnostics and inhibitors for amyloid diseases*
- The assigned IBC primary reviewer presented the primary review.
- This lab studies novel peptide based amyloid inhibitors that bind the toxic oligomers during amyloidogenesis.
- This lab works with recombinant and wild type Risk Group 2 pathogens as well as pathogenic and non-pathogenic E. coli and human blood, tissue, body fluids, and cell lines.
- The lab inspection has been completed with all deficiencies addressed.
- The required trainings are complete.
- The committee examined the draft BUA letter.
- The IBC primary reviewer made a motion to approve the draft BUA for Dr. Daggett.
- The committee voted unanimously to approve the draft BUA for Dr. Daggett pending clarification on use of recombinant Risk Group 2 pathogens.

c. Fuller, Deborah, renewal, *Nucleic Acid Mediated Protein Expression*
- The assigned IBC primary reviewer presented the primary review.
This lab studies the production of biological protein directly in animal following injection of nucleic acids.
This lab works with recombinant or synthetic DNA used in macaques as well as in vitro work with non-human primate blood, tissue, body fluids, and cell lines at BSL-2.
A successful lab inspection has been completed with all deficiencies addressed.
The required trainings are complete except one staff member needs to complete the biosafety training.
The committee examined the draft BUA letter.
The IBC primary reviewer made a motion to approve the draft BUA for Dr. Fuller.
The committee voted unanimously to approve the draft BUA for Dr. Fuller pending BUA updates listing gene insert used.

d. Gale, Michael, change, *The Host Response to Virus Infection*
   - The assigned IBC Primary reviewer presented the primary review.
   - This lab studies novel zoonotic viral pathogens in wildlife, domestic animals and humans seeking to discover and characterize zoonotic potential.
   - This lab works with novel viral protein expression constructs transfected into human cells.
   - The committee had a discussion regarding plans for the overall project, what samples types would be received at the university, and the potential for select agent or Risk Group 3 or 4 nucleic acids to be identified. EH&S Biosafety will prepare a packet of information for each lab involved in the project.
   - The biosafety officer determined a lab inspection was not required for this change.
   - All required trainings are complete.
   - The committee examined the draft BUA letter.
   - The IBC primary reviewer made a motion to approve the draft BUA for Dr. Gale.
   - The committee voted unanimously to approve the draft BUA for Dr. Gale pending preparation of information to share with labs.

e. Giachelli, Cecilia, renewal, *Calcification and Cell Differentiation*
   - The assigned IBC Primary reviewer presented the primary review.
   - This lab studies how to determine cell sources and molecular pathways involved in formation of vascular and valvular calcification.
   - This lab works with plasmids, gammaretroviral vectors, and lentiviral vectors with and without oncogene inserts in human cell lines at BSL-2.
   - The biosafety officer determined a lab inspection was not required because the lab had been recently inspected.
   - Lab personnel have completed all required trainings.
   - The committee examined the draft BUA letter.
   - The IBC primary reviewer made a motion to approve the draft BUA for Dr. Giachelli.
   - The committee voted unanimously to approve the draft BUA for Dr. Giachelli.

f. Giachelli, Cecilia, renewal, *Inflammation and Ectopic Calcification*
   - The assigned IBC primary reviewer presented the primary review.
   - This lab studies therapeutic strategies regarding cell calcification in soft tissue.
   - This lab works with usage of plasmids, gammaretroviral vectors, and lentiviral vectors at BSL-2.
• BSOs determined a lab inspection was not required because the lab had been recently inspected.
• All required trainings are complete.
• The committee examined the draft BUA letter.
• The IBC Primary reviewer made a motion to approve the draft BUA for Dr. Giachelli.
• The committee voted to approve the draft BUA for Dr. Giachelli with one member not voting.

g. Hawkins, Brian, change, Research, Development, and Manufacturing of Pluripotent Stem Cells and Differentiated Cells for the Treatment of Human Disease
• The assigned IBC primary reviewer presented the primary review.
• This lab studies how to commercialize cells for research and clinical usage.
• This change adds third gen lentiviral vectors and adeno associated viral vectors without oncogenes as well as Sendai viral vectors with oncogenes at BSL-2.
• The biosafety officer determined a lab inspection was not required because the lab had been recently inspected.
• All required trainings are complete.
• The committee examined the draft BUA letter.
• The IBC primary reviewer made a motion to approve the draft BUA for Dr. Hawkins.
• The committee voted unanimously to approve the draft BUA for Dr. Hawkins.

h. Heshmati, Mitra, new, Mechanisms of anesthesia and delirium
• The assigned IBC primary reviewer presented the primary review.
• This lab studies cellular and behavioral mechanisms of arousal from general anesthesia.
• This lab works with in vivo work with mice injected with adenovirus associated viral vectors in ABSL-1 and BSL-1.
• The lab inspection was completed but some deficiencies still need to be corrected.
• The lab has not submitted their IACUC protocol. The biosafety officer will not send the BUA until the IACUC has been reviewed.
• All required trainings are complete.
• The committee examined the draft BUA letter.
• The IBC primary reviewer made a motion to approve the draft BUA for Dr. Heshmati.
• The committee voted unanimously to approve the draft BUA for Dr. Heshmati pending BUAA revision, completion of inspection, and IACUC submission.

i. Kiem, Hans-Peter, change, Strategies to Improve Hematopoietic Stem Cell Transduction
• The assigned IBC primary reviewer presented the primary review.
• This lab studies gene therapy as a treatment modality for genetic disorders and acquired diseases using a non-human primate model.
• This change adds gene delivery via a nanolipid carrier or nanolipid material.
• The biosafety officer determined a lab inspection was not required for this change.
• All required trainings are complete.
• The committee examined the draft BUA letter.
• The IBC Primary reviewer made a motion to approve the draft BUA for Dr. Kiem.
• The committee voted unanimously to approve the draft BUA for Dr. Kiem.

j. King, Neil, change, Protein Nanoparticles for Biomedical Applications in Mice and Rats
• The assigned IBC primary reviewer presented the primary review.
• This lab studies the biomedical applicability of protein nanomaterials and the computational design of proteins using synthetic genes.
• This change adds recombinant nucleic acids for in vivo use in mice.
• The biosafety officer determined a lab inspection was not required.
• All required trainings are complete.
• The committee examined the draft BUA letter.
• The IBC primary reviewer made a motion to approve the draft BUA for Dr. King.
• The committee voted unanimously to approve the draft BUA for Dr. King.

k. Manicone, Anne, renewal, *MMPs in Repair and Immunity*
• The assigned IBC Primary reviewer presented the Primary review.
• This lab studies how immune cells regulate lung injury and immune response to lung injury.
• This lab works with in vitro usage of siRNA, plasmids, adeno-associated viral vectors, and lentiviral vectors to transfect and transduce cells. Risk Group 2 microorganisms including Pseudomonas aeruginosa, influenza mouse adapted strains, Staphylococcus aureus, and Streptococcus pneumonia will be used in vivo in mouse models.
• A successful lab inspection is complete with all deficiencies addressed.
• All required trainings are complete.
• The committee examined the draft BUA letter.
• The IBC primary reviewer made a motion to approve the draft BUA for Dr. Manicone.
• The committee voted unanimously to approve the draft BUA for Dr. Manicone pending third generation lentiviral information, revision of BUAA and IACUC.

l. Mitchell, Patrick, change, *Evolutionary, genetic, and molecular basis of host-pathogen interactions*
• The assigned IBC Primary reviewer presented the Primary review.
• This lab studies how the immune system responds to microbial infection and investigates host-pathogen interactions
• This change adds cholera strains and mutants to approved rooms.
• The biosafety officer determined a lab inspection was not required.
• The lab has not submitted their IACUC protocol. The biosafety officer will not send the BUA until the IACUC has been reviewed.
• All required trainings are complete.
• The committee examined the draft BUA letter.
• The IBC primary reviewer made a motion to approve the draft BUA for Dr. Mitchell.
• The Committee voted unanimously to approve the draft BUA for Dr. Mitchell pending BUAA revisions and IACUC submission.

m. Murphy, Sean, renewal, *Immunity to malaria infection*
• The assigned IBC Primary reviewer presented the Primary review.
• This lab studies immunology and diagnostics of malaria in an infected mouse model.
• This lab works with in vitro work with human cells transduced with adeno-associated viral vectors, human and mouse cell lines transfected with plasmids, and in vivo studies with mice transduced with adeno-viral vectors.
• Lab Inspection has been completed with no deficiencies identified.
• All required trainings are completed.
• The committee examined the draft BUA letter.
• The IBC Primary reviewer made a motion to approve the draft BUA for Dr. Murphy.
• The Committee voted unanimously to approve the draft BUA for Dr. Murphy pending submission of the IACUC protocol.

n. Neumaier, John, renewal, *Regulation of Serotonin Receptors*
   • The assigned IBC Primary reviewer presented the Primary review.
   • This lab studies the regulation of serotonin in the brain and behavioral outcomes using viral mediated gene transfer, drugs, gene modification, and molecular biology.
   • This lab works with in vitro and in vivo usage of adeno-associated viral vectors, replication deficient herpes simplex virus, and canine adenovirus in human, rat, and non-human primate cell lines.
   • The biosafety officer determined a lab inspection was not required.
   • All required trainings are complete.
   • The committee examined the draft BUA letter.
   • The IBC Primary reviewer made a motion to approve the draft BUA for Dr. Neumaier.
   • The Committee voted unanimously to approve the draft BUA for Dr. Neumaier pending BUA application and IACUC protocol revisions.

o. Odom, Guy, renewal, *Cardiopulmonary gene therapy for muscular dystrophy*
   • The assigned IBC Primary reviewer presented the Primary review.
   • This lab studies the development of gene therapies for potential treatment and cures for muscular dystrophy in mouse models.
   • This lab works with in vitro and in vivo gene delivery using adeno-associated viral vectors and transfection of plasmids into human and mouse cells as well as mice in ABSL-1.
   • A successful lab inspection is complete with all deficiencies addressed.
   • All required trainings are complete.
   • The committee examined the draft BUA letter.
   • The IBC Primary reviewer made a motion to approve the draft BUA for Dr. Odom.
   • The Committee voted unanimously to approve the draft BUA for Dr. Odom pending IACUC submission.

p. Smith, Jason, renewal, *Antiviral Mechanisms of Defensins*
   • The assigned IBC Primary reviewer presented the Primary review.
   • This lab studies the role of defensin peptides in mucosal defense mechanisms to modify pathogenesis of viral and bacterial agents and viral trophism.
   • This lab works with usage of viral vectors and recombinant Risk Group 2 organisms in vitro and in vivo using human, non-human primate, and other cell lines as well as transgenic mice.
   • A successful lab inspection is complete with all deficiencies addressed.
   • All required trainings are complete.
   • The committee examined the draft BUA letter.
   • The IBC Primary reviewer made a motion to approve the draft BUA for Dr. Smith.
• The Committee voted unanimously to approve the draft BUA for Dr. Smith pending IACUC submission.

q. Sniadecki, Nathan, change, Cell therapy in mice and rats
• The assigned IBC Primary reviewer presented the Primary review.
• This lab studies engraftment using xenografted human stem cells in mouse hearts.
• This change adds induced pluripotent stem cells transduced with third generation lentiviral vectors.
• The biosafety officer determined a lab inspection was not required.
• All required trainings are complete.
• The committee examined the draft BUA letter.
• The IBC Primary reviewer made a motion to approve the draft BUA for Dr. Sniadecki.
• The Committee voted unanimously to approve the draft BUA for Dr. Sniadecki.

r. Stevens, Kelly, renewal, Regenerative Technologies
• The assigned IBC Primary reviewer presented the Primary review.
• This lab studies development of cell-based treatments for patients with heart or liver failure using induced pluripotent stem cells.
• This lab works with includes third gen lentiviral vectors, adeno associated viral vectors, and human cell lines.
• The biosafety officer determined a lab inspection was not required as the lab had recently been inspected.
• All required trainings are complete.
• The committee examined the draft BUA letter.
• The IBC Primary reviewer made a motion to approve the draft BUA for Dr. Stevens.
• The Committee voted unanimously to approve the draft BUA for Dr. Stevens.

• The assigned IBC Primary reviewer presented the Primary review.
• This lab studies development and discovery of new therapeutic drugs needed for infections, particularly parasitic infections.
• This lab uses recombinant microorganisms in vitro and in mice.
• This lab works with novel viral protein expression transfected into human cells, E. coli, and baculovirus.
• The biosafety officer determined a lab inspection was not required as the lab had recently been inspected.
• All required trainings are complete.
• The committee examined the draft BUA letter.
• The IBC Primary reviewer made a motion to approve the draft BUA for Dr. Van Voorhis.
• The Committee voted unanimously to approve the draft BUA for Dr. Van Voorhis pending preparation of information to share with labs.

t. Zheng, Ning, renewal, Protein Structure Biology - Dr. Ning Zheng Lab
• The assigned IBC Primary reviewer presented the Primary review.
This lab studies the atomic structure of enzymes and protein complexes that modify other proteins’ structures.
This lab works with 1st/2nd generation lentiviral vectors transduced in human cells as well as plasmid transfected E. coli and insect cells.
The biosafety officer determined a lab inspection was not required as the lab had recently been inspected.
All required trainings are complete.
The committee examined the draft BUA letter.
The IBC Primary reviewer made a motion to approve the draft BUA for Dr. Zheng.
The Committee voted unanimously to approve the draft BUA for Dr. Zheng.

8. SUBCOMMITTEE REPORTS:

u. West, Timothy, renewal, Host Genetics and Response to Infection
   Three members of the IBC served as the Subcommittee Reviewers. One of the Subcommittee Reviewers presented the Subcommittee Report.
   This lab studies how genetic variations and other host elements alter response to infections in the lung.
   This lab works with recombinant Risk Group 3 microorganisms including B pseudomallei mutants administered in vitro and in vivo in BSL-3 facilities. Recombinant Risk Group 2 microorganisms are worked within BSL-2 facilities. Work conducted with human cells transduced with 3rd generation lentiviral vectors as well as transfected human cell lines.
   A successful lab inspection is still pending.
   All required trainings are complete.
   The project requires DURC renewal.
   The committee examined the draft BUA letter.
   A member made a motion to approve the draft BUA letter for Dr. West. Another member seconded the motion.
   The Committee voted unanimously to approve the draft BUA for Dr. West pending completion of inspection, DURC and IACUC.

10. FOR YOUR INFORMATION:

11. ISSUES FROM THE FLOOR & PUBLIC COMMENTS: There were no issues from the floor, and no public comments.

12. MEETING ADJOURNED AT APPROXIMATELY 11:59 P.M.